Effect analysis of entecavir and adefovir ester combined with lamivudine in treating HBeAg-positive chronic hepatitis B

doi:10.3877/cma.j.issn.2095-2015.2018.02.002

Abstract

Abstract:

Objective

To compare the effect and safety of entecavir(ETV)and adefovir ester combined with lamivudine(ADV+ LAM)for HBeAg-positive chronic hepatitis B(CHB).

Methods

A total of 110 HBeAg-positive CHB patients were selected in General Hospital of Jinan Military Command from July 2012 to July 2015, and they were randomly divided into ETV group(50 cases)and ADV+ LAM group(60 cases). The HBV-DNA negative conversion ratio, HBeAg seroconversion rate, alanine aminotransferase(ALT)recovery rate and adverse event rate were observed 48 and 96 weeks after treatment.

Results

The HBV-DNA negative conversion ratio(ETV vs.ADV+ LAM: 48 weeks 20 vs.15, 96 weeks 35 vs.45)and ALT recovery rate(ETV vs.ADV+ LAM: 48 weeks 40 vs.44, 96 weeks 48 vs.56)of the two groups were both improved 48 and 96 weeks after treatment, but the difference was not statistically significant(P>0.05). The difference of the HBeAg seroconversion rate between the two groups was not statistically significant for the first 48 weeks(ETV vs.ADV+ LAM: 48 weeks 10 vs.8). As time went on, the HBeAg seroconversion rate of ETV group was higher than that of ADV+ LAM group(96 weeks 18 vs.9).

Conclusion

In the treatment of HBeAg-positive CHB patients using ETV and ADV+ LAM, the more remarkable effect of HBeAg seroconversion rate of ETV is correlated with the longer follow-up, and the drug is safer.

Key words: Hepatitis B, HBeAg-positive, Entecavir, Adefovir ester

Danping Yin, Wei Han. Effect analysis of entecavir and adefovir ester combined with lamivudine in treating HBeAg-positive chronic hepatitis B[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(02): 53-56.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2018.02.002

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2018/V08/I02/53

Figures/Tables 2

References 20

1	European Association for the Study of the Liver.EASL 2017 Clinical Practice Guildelines on the management of Hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
2	WHOGuidelinesApproved by theGuidelinesReview Committee. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection[J]. Geneva: World Health Organization, 2015.
3	杨静．拉米夫定联合阿德福韦酯与恩替卡韦单药治疗慢性乙型肝炎的疗效比较[J]．皖南医学院学报，2015，34(1): 56-58.
4	孙兴．拉米夫定联合阿德福韦酯与恩替卡韦单药治疗慢性乙型肝炎的疗效对比[J]．现代诊断与治疗，2015，26(19): 4407-4408.
5	European Association for the Study of the Liver.EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(2): 167-185.
6	吴丽萍，张建军，杜瑞清，等．HBeAg阴性与阳性慢性乙型肝炎的临床病理对比研究[J]．临床肝胆病杂志，2009，25(3): 175-177.
7	刘健，高志文，徐辉，等．拉米夫定和阿德福韦酯与恩替卡韦治疗乙型肝炎肝硬化的疗效对比[J]．西藏医学，2017，38(1): 42-44.
8	Terrault NA, Bzowej NH, Chang KM, et al.AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283.
9	陈春，伍思国，杨智娟，等．恩替卡韦联合阿德福韦酯治疗拉米夫定耐药慢乙型肝炎的临床观察[J]．广东医学院学报，2014，32(6): 807-808.
10	Lok AS, McMahon BJ, Brown RS, et al.Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis[J]. Hepatology, 2016, 63(1): 284-306.
11	杨雅芳，杨小平，董建国，等．ETV和阿德福韦酯分别治疗HBeAg阳性慢性乙型肝炎近期疗效分析[J]．临床肝胆病杂志，2010，26(3): 326-327.
12	王君萍．拉米夫定联合阿德福韦酯或恩替卡韦治疗慢性乙型肝炎患者的疗效评价[J]．健康大视野，2013，21(1): 6.
13	刘爱平，耿爱文，李阳．拉米夫定耐药慢性乙型肝炎患者应用拉米夫定联合阿德福韦酯或恩替卡韦治疗的疗效评价[J]．吉林医学，2013，34(2): 246-246.
14	杨庆文．拉米夫定联合阿德福韦酯治疗拉米夫定和阿德福韦酯序贯治疗耐药40例[J]．中国中医药现代远程教育，2012，10(22): 36-38.
15	龚菁，郭风彩，李大春，等．联合阿德福韦酯或换用恩替卡韦治疗拉米夫定耐药慢性乙型肝炎患者的临床观察[J]．中国医药指南，2012，10(27): 23-24.
16	曹民．拉米夫定耐药后的治疗选择[J]．现代医药卫生，2012，28(9): 1439-1439.
17	高冬梅．中心拉米夫定耐药的慢性乙型肝炎治疗策略[J]．中国医药指南，2012，10(8): 146-148.
18	邰立慧．阿德福韦联合拉米夫定与恩替卡韦治疗耐药性慢性乙型肝炎疗效比较[J]．中国血液流变学杂志，2011，21(2): 298-299.
19	Ryu HJ, Lee JM, Ahn SH, et al.Efficacy of adefovir add-onlamivudine rescue therapy compared with switching to entecavirmonotherapy in patients with lamivudine-resistant chronic hepatitis B[J]. J Med Virol, 2010, 82(11): 1835-1842.
20	骆晓霞，陈康鉴．拉米夫定联合阿德福韦酯或恩替卡韦治疗拉米夫定和阿德福韦酯序贯治疗耐药患者的研究[J]．齐齐哈尔医学院学报，2010，20(20): 3286-3287.

组别	例数	年龄(岁，±s)	性别比男/女	BMI(kg/m²，±s)	HBV DNA(log10 copies/ml，±s)	ALT(U/L，±s)
ETV组	50	40.6±11.5	37/13	22.6±3.5	7.2±1.7	121.1±64.1
ADV＋LAM组	60	39.2±10.5	40/20	21.3±4.7	7.5±1.3	130.3±51.5
t/χ²值	?	0.67	0.70	1.61	1.05	1.11
P值	?	0.505	0.4	0.108	0.296	0.267

组别	例数	年龄(岁，±s)	性别比男/女	BMI(kg/m²，±s)	HBV DNA(log10 copies/ml，±s)	ALT(U/L，±s)
ETV组	50	40.6±11.5	37/13	22.6±3.5	7.2±1.7	121.1±64.1
ADV＋LAM组	60	39.2±10.5	40/20	21.3±4.7	7.5±1.3	130.3±51.5
t/χ²值	?	0.67	0.70	1.61	1.05	1.11
P值	?	0.505	0.4	0.108	0.296	0.267

组别	例数	HBV DNA转阴	HBeAg转阴率	ALT复常率
48周ETV组	50	20 (40)	10(20)	40(80)
ADV＋LAM组	60	15 (25)	8(13)	44(73)
t/χ²值	?	2.83	0.89	0.67
P值	?	0.10	0.35	0.408
96周ETV组	50	35(70)	18(36)	48(96)
ADV＋LAM组	60	45(67)	9(15)	56(93)
t/χ²值	?	0.34	6.49	0.37
P值	?	0.56	0.015	0.53

组别	例数	HBV DNA转阴	HBeAg转阴率	ALT复常率
48周ETV组	50	20 (40)	10(20)	40(80)
ADV＋LAM组	60	15 (25)	8(13)	44(73)
t/χ²值	?	2.83	0.89	0.67
P值	?	0.10	0.35	0.408
96周ETV组	50	35(70)	18(36)	48(96)
ADV＋LAM组	60	45(67)	9(15)	56(93)
t/χ²值	?	0.34	6.49	0.37
P值	?	0.56	0.015	0.53

[1]	Jiansong Gao, Xiaoxiao Chen, Ting Feng, Jianfeng Bao, Shufang Wei, Lin Pan. Ultrasonic elastography based multiparameteric decision tree model for assessment of grade of liver fibrosis in patients with chronic hepatitis B [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 923-929.
[2]	Qinyuan Li, Changfeng Dong, Cheng Feng, Zhiyan Li, Li Liu, Binghao He, Wei Jiang, Wenshuo Tian, Shuai Yang. Multimodal method based on elastography to stage liver fibrosis in chronic hepatitis B patients [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(09): 976-982.
[3]	Xiaoman Zhang, Xiaoqiu Ma, Zhengju Xu, Chunyu Zhang, Caiting He. Effect of drug-resistant mutations in reverse transcriptase region of hepatitis B virus on the level of serum hepatitis B surface antigen [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 324-332.
[4]	Yingying Wang, Ping Xie. Risk factors of liver injury in patients with hepatitis B virus infection and pulmonary tuberculosis and predictive model construction [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(04): 267-273.
[5]	Min Quan, Gaiqing Yan, Huichun Xing. Changes of soluble-Fas level in the optimal treatment of patients with chronic hepatitis B with poor antiviral response [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(01): 16-23.
[6]	Xiyan Zheng, Zheng Zhou, Fangping He, Zhiqun Lin, Fei Du, Qin Xie, Shaoping Wang, Xianjie Shi. Risk factors for the prognosis of metabolic syndrome and hepatitis B virus related hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 104-109.
[7]	Fangyuan Wu, Xia Sun, Changfeng Lin, Zhensheng Zhang. Risk factors of HBV-associated cirrhosis complicated with acute upper gastrointestinal bleeding [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 45-47.
[8]	Xuexue Lei, Ying Yu, Hongyan Li. Clinical research of multimodal prehabilitation optimization program in patients with hepatitis B virus-related liver cirrhosis awaiting liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 158-163.
[9]	Shudian Chen, Yun Liang, Yuan Liao, Yang Wang. Prognostic value of complement C3 in patients with HBV-related acute-on-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 562-566.
[10]	Yong Li, Chuan Lan, Bin Wu, Guangnian Zhang, Jingdong Li. Predictive value of preoperative platelet-albumin score for postoperative prognosis of cirrhotic hepatocellular carcinoma patients [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 412-416.
[11]	Yuyang Xu, Yunfu Lyu, Baochun Wang. Progress of surgical treatments for splenomegaly in patients with hepatitis B cirrhotic portal hypertension [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 469-473.
[12]	Fanbiao Kong, Jianrong Yang. Progress in understanding of relationship between underlying liver diseases and liver metastasis of colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 818-822.
[13]	Lichao Lian, Ziyue Fan, Xin Zhang, Li. Bai. Predictive value of combined detection of urine KIM-1, NGAL, and RBP for early renal injury in patients with chronic hepatitis B [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(04): 414-418.
[14]	Chong Chen, Ranran You, Min Wang, Haojie Zhou. Blood safety analysis of single-HBsAg-reagent(+)/NAT(-) blood donors [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(02): 95-98,104.
[15]	Huiping Wei, Yingming Guo, Guirong Liu, Zongyou Wu, Qiuqing Weng. Application value of superoxide dismutase test in hepatitis B virus related liver disease [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(01): 21-26.

Please choose a citation manager

Content to export